This Time-Tested Strategy Could Be Your Winning Lottery Ticket

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

Author Image for Steve Christ
About the Author

Steve Christ is the Executive Editor for Money Morning. Steve first started trading stocks in the wake of the 1987 market crash - and was immediately hooked. In 2006, he launched his career in the financial press with a prescient call that home prices would fall 30% and hundreds of banks would fail. Before taking over Money Morning, he was the founding editor of The Wealth Advisory, an income newsletter. Today Steve specializes in the housing market and has appeared on radio and TV programs across the country. He resides in his hometown of Baltimore, Md., with his wife and three children.

... Read full bio